XML 42 R23.htm IDEA: XBRL DOCUMENT v3.8.0.1
Equity-Based Compensation Plans
12 Months Ended
Dec. 31, 2017
Equity-Based Compensation Plans [Abstract]  
Equity-Based Compensation Plans

Note 15. Equity-Based Compensation Plans

 

The Company recorded total stock-based compensation expense of $1,095,000, $714,000 and $710,000 for the years ended December 31, 2017, 2016, and 2015, respectively. Of the $1,095,000 in expense that was recorded in 2017, approximately $320,000 related to the June 1, 2017 director grants discussed below, and is classified as “other operating expenses” in the Consolidated Statements of Income. The remaining $775,000 in expense relates to the employee grants discussed below and is recorded as “salaries expense.” Stock based compensation is reflected as an adjustment to cash flows from operating activities on the Company’s Consolidated Statement of Cash Flows. The Company recognized $405,000, $264,000, and $277,000 of income tax benefits related to stock based compensation expense in the income statement for the years ended December 31, 2017, 2016, and 2015, respectively.

 

At December 31, 2017, the Company had the following equity-based compensation plans: the First Bancorp 2014 Equity Plan and the First Bancorp 2007 Equity Plan. The Company’s shareholders approved all equity-based compensation plans. The First Bancorp 2014 Equity Plan became effective upon the approval of shareholders on May 8, 2014. As of December 31, 2017, the First Bancorp 2014 Equity Plan was the only plan that had shares available for future grants, and there were 809,690 shares remaining available for grant.

 

The First Bancorp 2014 Equity Plan is intended to serve as a means to attract, retain and motivate key employees and directors and to associate the interests of the plans’ participants with those of the Company and its shareholders. The First Bancorp 2014 Equity Plan allows for both grants of stock options and other types of equity-based compensation, including stock appreciation rights, restricted stock, restricted performance stock, unrestricted stock, and performance units.

 

Recent equity grants to employees have either had performance vesting conditions, service vesting conditions, or both. Compensation expense for these grants is recorded over the various service periods based on the estimated number of equity grants that are probable to vest. No compensation cost is recognized for grants that do not vest and any previously recognized compensation cost will be reversed. The Company issues new shares of common stock when options are exercised.

 

Certain of the Company’s stock option grants contain terms that provide for a graded vesting schedule whereby portions of the award vest in increments over the requisite service period. The Company recognizes compensation expense for awards with graded vesting schedules on a straight-line basis over the requisite service period for each incremental award. Compensation expense is based on the estimated number of stock options and awards that will ultimately vest. Over the past five years, there have only been minimal amounts of forfeitures, and therefore the Company assumes that all awards granted without performance conditions will become vested.

 

The Company typically grants shares of common stock to each non-employee director in June of each year. On June 1, 2017, the Company granted 11,190 shares of common stock to non-employee directors (1,119 shares per director), at a fair market value of $28.59 per share, which was the closing price of the Company’s common stock on that date, which resulted in $320,000 in expense. On June 1, 2016, the Company granted 6,584 shares of common stock to non-employee directors (823 shares per director), at a fair market value of $19.56 per share, which was the closing price of the Company’s common stock on that date, which resulted in $129,000 in expense.

 

The Company’s senior officers receive their annual bonus earned under the Company’s annual incentive plan in a mix of 50% cash and 50% stock, with the stock being subject to a three year vesting term. In the last three years, a total of 55,648 shares of restricted stock have been granted related to performance in the preceding fiscal years. Total compensation expense associated with those grants was $758,000 and is being recognized over the respective vesting periods. The Company recorded $282,000, $220,000 and $93,000, for the years ended December 31, 2017, 2016 and 2015, respectively.

 

In the last three years, the Compensation Committee of the Company’s Board of Directors also granted 130,059 shares of stock to various employees of the Company to promote retention. The total value associated with these grants amounted to $2.8 million, and is being recorded as expense over their three year vesting periods. For 2017, 2016, and 2015, total compensation expense related to these grants was $491,000, $366,000, and $488,000, respectively. All grants were issued based on the closing price of the Company’s common stock on the date of the grant.

 

Based on the vesting schedules of the shares of restricted stock currently outstanding, the Company expects to record $733,000 in stock-based compensation expense in 2018.

 

The following table presents information regarding the activity during 2015, 2016, and 2017 related to the Company’s outstanding restricted stock:

 

   Long-Term Restricted Stock 
   Number of
Units
   Weighted-
Average Grant-
Date Fair Value
 
         
Nonvested at January 1, 2015   50,438   $11.42 
           
Granted during the period   65,618    17.28 
Vested during the period   (20,117)   17.44 
Forfeited or expired during the period   (40,610)   9.87 
           
Nonvested at December 31, 2015   55,329   $17.31 
           
Granted during the period   65,255    19.40 
Vested during the period   (28,794)   17.79 
Forfeited or expired during the period        
           
Nonvested at December 31, 2016   91,790   $18.65 
           
Granted during the period   48,322    31.05 
Vested during the period   (28,275)   20.05 
Forfeited or expired during the period   (8,535)   18.34 
           
Nonvested at December 31, 2017   103,302   $24.09 

 

In years prior to 2009, stock options were the primary form of equity grant utilized by the Company. The stock options had a term of ten years. In a change in control (as defined in the plans), unless the awards remain outstanding or substitute equivalent awards are provided, the awards become immediately vested.

 

At December 31, 2017, there were 38,689 stock options outstanding related to the two First Bancorp plans, with exercise prices ranging from $14.35 to $16.81.

 

The following table presents information regarding the activity since January 1, 2015 related to all of the Company’s stock options outstanding:

 

   Options Outstanding 
   Number of
Shares
   Weighted-
Average
Exercise
Price
   Weighted-
Average
Contractual
Term (years)
   Aggregate
Intrinsic
Value
 
                 
Balance at January 1, 2015   179,102   $18.55           
                     
   Granted                  
   Exercised   (7,353)   15.20        $19,843 
   Forfeited                  
   Expired   (54,341)   19.93           
                     
Balance at December 31, 2015   117,408   $18.12           
                     
   Granted                  
   Exercised   (23,710)   15.84        $81,894 
   Forfeited                  
   Expired   (33,750)   21.39           
                     
Balance at December 31, 2016   59,948   $17.18           
                     
   Granted                  
   Exercised   (21,259)   19.16        $236,584 
   Forfeited                  
   Expired                  
                     
Outstanding at December 31, 2017   38,689   $16.09    0.67   $743,679 
                     
Exercisable at December 31, 2017   38,689   $16.09    0.67   $743,679 

 

 

In 2017, 2016 and 2015, the Company received $287,000, $375,000 and $112,000, respectively, as a result of stock option exercises.

 

The following table summarizes information about the stock options outstanding at December 31, 2017:

 

   Options Outstanding   Options Exercisable 

 

 

Range of

Exercise Prices

  Number
Outstanding
at 12/31/17
   Weighted-
Average
Remaining
Contractual Life
   Weighted-
Average
Exercise
Price
   Number
Exercisable
at 12/31/17
   Weighted-
Average
Exercise
Price
 
                     
$13.27 to $15.48   9,000    1.4   $14.35    9,000   $14.35 
$15.48 to $17.70   29,689    0.4    16.61    29,689    16.61 
    38,689    0.7   $16.09    38,689   $16.09